• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive,
infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and …

Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in
everyday clinical practice, but the diagnosis continues to be made in patients with late-stage …

This guideline describes the approach and expertise needed for the genetic evaluation of
cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the …

Aims Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease
predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF …

Aim To investigate the prevalence of amyloid cardiomyopathy (AC) and the diagnostic
accuracy of echocardiographic red flags of AC among consecutive adult patients …

Purpose The purpose of this document is to provide updated guidance for the genetic
evaluation of cardiomyopathy and for an approach to manage secondary findings from …

Background—Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an
underappreciated cause of morbidity and mortality in the aging population. The aims of this …

Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and
transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded …